Direktorat Registrasi ObatValid

DAYVIGO

BPOM Number: DKL2606103317A1
Approved: 23 June 2026
Expiry: 17 May 2027
Form: TABLET SALUT SELAPUT

About This Registration

DAYVIGO is a BPOM-registered direktorat registrasi obat in Indonesia, registered under number DKL2606103317A1. Its current registration status is Valid, with the licence valid until 17 May 2027. The product is registered to EISAI INDONESIA - INDONESIA. BPOM first approved this registration in June 2026. All registration data is sourced directly from the official BPOM public database and updated daily.

Registration data updated by BPOM

This product's registration details were changed on 30 June 2026. This may reflect a status change, renewal, or correction by BPOM.

Registration Details

Application: newaero
Packaging: DUS, 2 BLISTER @ 14 TABLET SALUT SELAPUT
Department: Direktorat Registrasi Obat
Data Last Updated: 30 June 2026

Retail Audit Service

Get detailed market intelligence for this product across Indonesian retail channels

Multiple cities available

Custom questionnaires

Professional shoppers

Detailed reporting

Starting from $50 per city

What's included in the audit service?

Stock availability and positioning verification

Price checking and competitor analysis

Display quality and promotional material assessment

Store condition and customer experience evaluation

Custom questions tailored to your research needs

Professional photographs and detailed reports

Registered Owners

EISAI INDONESIA - INDONESIA
KAB. BOGOR
NPWP: 010005262052000
owner
View profile →

Manufacturing Sites

EISAI INDONESIA - INDONESIA
KAB. BOGOR
primary
View profile →

Ingredients (1)

LEMBOREXANT

Market Intelligence

Owner Portfolio: EISAI INDONESIA - INDONESIA holds 34 BPOM registrations
Manufacturer Scale: EISAI INDONESIA - INDONESIA produces 34 registered products
Registration Age: Registered for 2 months
Expiry Status: Expires in 8 months
Update Status: Recently updated (70 days ago)

FDA Cross-Reference

via openFDA

Generic Name: LEMBOREXANT
Product Type: HUMAN PRESCRIPTION DRUG
Route of Administration: ORAL

Data sourced from the U.S. FDA drug label database (openFDA). May not exactly match this product variant.

Is this your product?